Q-omics provides the consensus-scored TPGS1 profile across patient tissues and cancer cell-line models. TPGS1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TPGS1 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, TPGS1 RNA expression shows 16,182 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where TPGS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPGS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPGS1 survival associations across molecular data types. TPGS1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPGS1 RNA expression–survival associations across cancer types. High TPGS1 expression shows unfavorable associations in ACC, UCS, LGG and CESC, but favorable associations in SCLC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TPGS1 RNA expression.
This table summarizes TPGS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TPGS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPGS1 shows lower tumor expression in KICH and LUAD and higher tumor expression in COAD, LIHC, HNSC and CHOL. The COAD box plot shows higher TPGS1 RNA expression in tumor versus normal tissue (log2 FC = +0.956, t-test p < 0.001).
This table shows molecular features associated with TPGS1 in patient tissues and cancer cell lines. In patient samples, TPGS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TPGS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
